Abbratech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

AbbraTech is an early-stage biotech leveraging its novel EPIVOLVE platform to discover antibodies against difficult, low-immunogenicity targets. Founded by a team of experienced serial entrepreneurs, including inventor Dr. Michael P. Weiner, the company aims to create next-generation therapeutics through partnerships. While currently in a pre-revenue, platform-validation stage, its technology addresses a significant gap in the antibody discovery landscape, targeting a broad range of human diseases.

OncologyImmunologyInfectious Diseases

Technology Platform

EPIVOLVE platform for recombinant antibody discovery designed to generate antibodies against low-immunogenicity and immune-tolerant targets, enabling site-specific, structure-guided discovery.

Opportunities

AbbraTech's platform targets the substantial 'undruggable' space within the therapeutic antibody market, offering potential first-in-class therapies.

Successfully validating the technology through an industry partnership could rapidly increase its value and attract significant investment or acquisition interest.

Risk Factors

The company faces high technical risk that its platform may not perform as expected against the most challenging targets.

As a pre-revenue startup, it is also dependent on securing ongoing funding and initial partnership deals to validate its business model and survive.

Competitive Landscape

AbbraTech competes in a crowded field of antibody discovery technologies, including established phage/yeast display platforms, transgenic animal systems, and emerging computational/AI-driven design tools. Its differentiation hinges on proving superior efficacy against targets that fail with these conventional approaches.

More companies in Biologics / Biosimilars →More companies in United States →